<DOC>
	<DOC>NCT01435525</DOC>
	<brief_summary>The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.</brief_summary>
	<brief_title>Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation</brief_title>
	<detailed_description>Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Inclusion criteria: Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer H.pylori negative at the time when the triple therapy is started</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>triple therapy</keyword>
	<keyword>Helicobacter pylori</keyword>
	<keyword>eradication</keyword>
	<keyword>Nexium</keyword>
</DOC>